TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06017141

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and tissue sample collection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Citrate
Description: Given via injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate
Description: Given via injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Given via inhalation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Procedure
Description: Undergo SOC surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo SOC surgery
Study: NCT05427721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymol
Description: 200 mg each 8 hours for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thymol
Description: 200 mg each 8 hours for 90 days
Study: NCT05292014

Intervention type: DEVICE
Intervention: ANGIOLITE
Description: Patients in whom treatment with ANGIOLITE has been attempted
Study: NCT04332601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fatigue Management Therapy
Description: 14 sessions of 1h CBT intervention

Intervention type: OTHER
Group type: OTHER
Intervention: TAU (Treatment as usual)
Description: No CBT intervention
Study: NCT05823701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 20 mg (4 capsules), d1, d4, d8, d11 orally per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 100mg d1- d5 subcutaneous injection per cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: obinutuzumab
Description: 1000mg d4 intravenous infusion per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal mitoxantrone
Description: 20mg/m2 d5 intravenous infusion per cycle
Study: NCT06350851

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biological samples collection (blood drawing + feces)
Description: Blood and feces samples will be collected from each volunteer.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biological samples collection (blood drawing + feces)
Description: Blood and feces samples will be collected from each volunteer.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biological samples collection (blood drawing + feces)
Description: Blood and feces samples will be collected from each volunteer.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Biological samples collection (blood drawing + feces)
Description: Blood and feces samples will be collected from each volunteer.
Study: NCT05922176

Intervention type: OTHER
Intervention: Evaluation of clinical indicators, Sample collection before& after immunotherapy
Description: A. Evaluation of clinical indicators before immunotherapy~1. Symptom Scale for Rhinitis: Total Nasal Symptom Score (TNSS), Rhnitis Quality of Life Questionnaire(RQLQ)~2. American house dust mite-specific immunogloblin G4 (sIgG4)~3. American house dust mite-specific immunogloblin E (sIgE)~B. Sample collection before immunotherapy~1. Skin: Skin test using minimally invasive microstructure patch stripping method~2. Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)~C. Evaluation of clinical indicators 4 to 6 months after immunotherapy~: Treatment is performed for about 4 months, and the progress of treatment is evaluated through the evaluation of the following clinical indicators.~same as examination in 'A'~D. Sample collection after 4 to 6 months of immunotherapy same as examination in 'B'

Intervention type: OTHER
Intervention: Sample collection before& after immunotherapy
Description: B. Sample collection before immunotherapy~1. Skin: Skin test using minimally invasive microstructure patch stripping method~2. Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)~D. Sample collection after 4 to 6 months of immunotherapy~1. Skin: Skin test using minimally invasive microstructure patch stripping method~2. Blood: Measurement of blood immunological indicators (Th2, Treg-related cytokine and blocking factor, etc.)
Study: NCT05851274

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transradial access
Description: In this group, the transradial access (TRA) was used, which was to puncture the radial artery and insert a radial sheath to establish a surgical pathway for embolization of the aneurysm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfemoral access
Description: In this group, transfemoral access (TFA) was used to embolize the aneurysms, which was to puncture the femoral artery and insert the femoral sheath to establish a surgical pathway for embolizing the aneurysm.
Study: NCT06651905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The patients were given 0.5 mcg /kg dexmedetomidine over 10 min via syringe pump, followed by 0.2-0.7 mcg/kg/hour until the end of intubation according to hemodynamics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Superior laryngeal nerve block
Description: The patients received an airway nerve block through bilateral superior laryngeal nerve block and trans-tracheal injection for recurrent laryngeal nerve.
Study: NCT06655064

Intervention type: OTHER
Intervention: None- Observational
Description: None- Observational

Intervention type: OTHER
Intervention: None- Observational
Description: None- Observational

Intervention type: OTHER
Intervention: None- Observational
Description: None- Observational
Study: NCT06654180

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthokeratology
Description: Orthokeratology is to a rigid contact lens with reverse design to flat the central cornea to correct the myopia, which is to use at night during sleep; DIMS and SVS are both spectacles to wear at daytime; DIMS has many tiny lenses at peripheral of the big lenses to make the peripheral retina myopic defocus during the daytime; SVS has only one focus while DIMS has many focuses made by the tiny segments lenses around the peripheral vision fields; DISK is a soft contact lens with peripheral myopic power design to make the myopic eyes defocus at peripheral during the daytime.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: defocus-incorporated multiple segment lenses (DIMS) spectacles
Description: It is the special lenses with peripheral lots of tiny segments of plus lenses around the center

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISK
Description: SVS

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Single-focus spectacles
Description: Myopic Glasses with mono-focus in each eye
Study: NCT06654934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: An initial dose of 40 mg/day will be administered for 1 week, followed by 30 mg/day for 1 week, 20 mg/day for 6 weeks, 15 mg/day for 4 weeks, 10 mg/day for 8 weeks, 5 mg/day for 4 weeks, 2.5 mg/day for 2 weeks after which the drug will be discontinued (cumulative prednisolone dose, 2485 mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: An initial dose of 40 mg/day will be administered for 1 week, followed by 30 mg/day for 1 week, 20 mg/day for 6 weeks, 15 mg/day for 4 weeks, 10 mg/day for 14 weeks, 5 mg/day for 24 weeks, 2.5 mg/day for 2 weeks after which the drug will be discontinued (cumulative prednisolone dose, 3605 mg).
Study: NCT05395104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Syrup for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefiderocol
Description: Liquid for intravenous infusion
Study: NCT03733067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abatacept
Description: Double-blind, placebo-controlled, intra-patient dose-escalation trial of abatacept for treating cytopenia in CTLA4 deficiency. Abatacept or placebo will be administered for 3 doses over 30 days, followed by 5 more months of administration at double the initial dose. If the participant s hematologic parameters normalize at Day 120 or onwards, the investigator may taper or discontinue concomitant medications aimed at treating cytopenia.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline packaged identically to abatacept, with volume matching that of the abatacept dosing by weight, and will be administered via IV infusion identically to abatacept
Study: NCT06493682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental (Motivational Interviews)
Description: Monitoring 'behaviour of healthcare demand procrastination, health beliefs regarding cervical cancer screenings, and screening participation' with motivational interviewing
Study: NCT06015451

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sub-symptom threshold exercise
Description: Aerob exercise at an intensity just below the intensity that provokes symptom exacerbation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sub-symptom threshold exercise
Description: Aerob exercise at an intensity just below the intensity that provokes symptom exacerbation.
Study: NCT06246708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-help app with information for grieving Syrian Refugees
Description: This study explores a self-help app for grieving Syrian refugees in Switzerland, featuring five chapters on grief, resources, space, negative thoughts, and future self-help. The Arabic app includes psychoeducational content, audio exercises, and videos. Users personalize it, save favorites, and set reminders. Tailored for Arabic-speaking refugees, it's accessible on iOS and Android, without invasive components. Participants complete one weekly chapter over five weeks. Data input is stored without manipulation. Accessible data includes completed chapters, subchapters, and feedback. The app promotes self-help, respecting cultural nuances for user engagement.

Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list
Description: Participants in the wait-list control group, receive access to the same intervention described above after a waiting period of 5 weeks.
Study: NCT04866654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/ML
Description: Nivolumab, 100 mg, 10 mg/ml
Study: NCT06134206

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trans-burr hole ultrasound
Description: All ultrasound examinations were conducted alongside the routine postoperative CT scan between 3-7 days postoperatively. To minimize potential influences of the patient's head position on the distribution and thickness of the subdural fluid, we first carried out the CT scan with the patient and their head in a supine position. Immediately after the CT scan, the patient remained on the same examination bed, and burr hole ultrasound was performed in the identical supine position. The burr hole was centered in the image, with the outer table surrounding the burr hole displayed as a horizontal line. The content of the burr hole could be differentiated by its higher echogenicity from the subdural residual hematoma or residual fluid. The brain's surface and overlying leptomeninges, however, displayed higher echogenicity compared to the subdural fluid. The subdural hematoma's thickness was measured at its maximum extent.
Study: NCT06059651

Intervention type: PROCEDURE
Intervention: Metabolic & Bariatric Surgery
Description: Roux-en-Y metabolic and bariatric surgery

Intervention type: PROCEDURE
Intervention: Metabolic & Bariatric Surgery
Description: Roux-en-Y metabolic and bariatric surgery
Study: NCT06493604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reproxalap Ophthalmic Solution (0.25%)
Description: Reproxalap Ophthalmic Solution (0.25%) administered six times over two consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Ophthalmic Solution
Description: Vehicle Ophthalmic Solution administered six times over two consecutive days
Study: NCT04617756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients receiving neoadjuvant therapy before radical nephrectomy
Description: Chemotherapy using either a combination of Gemcitabine/Cisplatin and neoadjuvant immunotherapy therapy with Durvalumab (MEDI 4736) or Chemotherapy with either Gemcitibine/Carboplatin and neoadjuvant immunotherapy therapy with Durvalumab (MEDI 4736)
Study: NCT06431009

Intervention type: OTHER
Intervention: Treatment-as-usual
Description: Patients will be treated and followed according to normal clinical treatment guidelines at the local psychiatric hospitals, which will not be affected by participation in the RMS cohort.

Intervention type: OTHER
Intervention: Treatment-as-usual
Description: Patients will be treated and followed according to normal clinical treatment guidelines at the local psychiatric hospitals, which will not be affected by participation in the RMS cohort.
Study: NCT05161832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nocebo
Description: Nocebo ultrasound with diagnosis of a fake shoulder cuff injury.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo ultrasound with no diagnosis of injury.
Study: NCT04536454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FPyGal
Description: Radiotracer for PET-imaging
Study: NCT05620043

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sculptra
Description: Biostimulator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiesse Plus
Description: Semi-permanent filler
Study: NCT06493877

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Retraining program after thoracic surgery
Description: An effort retraining program will be carried out, with respiratory physiotherapy, muscle strengthening exercises and aerobic exercise, for four weeks, every other day, with a duration of 75 minutes each session. Both the control and experimental groups will receive a common treatment: Muscle strength and aerobic resistance exercises will be performed following the F.I.T.T principle, working the main muscle groups against resistance (between 40% and 60% RM) performing three sets of ten repetitions of each one. It will begin with a warm-up and then a cool down with stretching. We will apply respiratory physiotherapy techniques to promote ventilation and drainage of secretions.~Next, the aerobic work is carried out according to the assigned group: treadmill with a positive slope (experimental group), treadmill with a negative slope (control 1) or cycle ergometer (group 2).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Retraining program after thoracic surgery
Description: An effort retraining program will be carried out, with respiratory physiotherapy, muscle strengthening exercises and aerobic exercise, for four weeks, every other day, with a duration of 75 minutes each session. Both the control and experimental groups will receive a common treatment: Muscle strength and aerobic resistance exercises will be performed following the F.I.T.T principle, working the main muscle groups against resistance (between 40% and 60% RM) performing three sets of ten repetitions of each one. It will begin with a warm-up and then a cool down with stretching. We will apply respiratory physiotherapy techniques to promote ventilation and drainage of secretions.~Next, the aerobic work is carried out according to the assigned group: treadmill with a positive slope (experimental group), treadmill with a negative slope (control 1) or cycle ergometer (group 2).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Retraining program after thoracic surgery
Description: An effort retraining program will be carried out, with respiratory physiotherapy, muscle strengthening exercises and aerobic exercise, for four weeks, every other day, with a duration of 75 minutes each session. Both the control and experimental groups will receive a common treatment: Muscle strength and aerobic resistance exercises will be performed following the F.I.T.T principle, working the main muscle groups against resistance (between 40% and 60% RM) performing three sets of ten repetitions of each one. It will begin with a warm-up and then a cool down with stretching. We will apply respiratory physiotherapy techniques to promote ventilation and drainage of secretions.~Next, the aerobic work is carried out according to the assigned group: treadmill with a positive slope (experimental group), treadmill with a negative slope (control 1) or cycle ergometer (group 2).
Study: NCT05863520

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Zones of Regulation
Description: ZOR is rooted in CBT principles and uses a metacognitive framework to increase awareness of feelings and to build regulation, prosocial skills, and overall wellness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facing Your Fears - School Based
Description: FYF-SB is a CBT program for managing anxiety in autistic youth.
Study: NCT05344768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: Moderate intensity aerobic exercise training will be applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: Moderate intensity aerobic exercise training will be applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-intensity interval exercise training
Description: High-intensity interval exercise training will be applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-intensity interval exercise training
Description: High-intensity interval exercise training will be applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance exercise training
Description: resistance exercise training will be applied

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance exercise training
Description: resistance exercise training will be applied

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: resistance exercise training
Description: resistance exercise training will be applied
Study: NCT06513286

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TherVacB (HEPLISAV B)
Description: Administration of the described combinations via the intramuscular route

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TherVacB (HEPLISAV B)
Description: Administration of the described combinations via the intramuscular route

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TherVacB (HEPLISAV B)
Description: Administration of the described combinations via the intramuscular route

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TherVacB (HEPLISAV B)
Description: Administration of the described combinations via the intramuscular route

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TherVacB (HEPLISAV B)
Description: Administration of the described combinations via the intramuscular route

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TherVacB (HEPLISAV B)
Description: Administration of the described combinations via the intramuscular route

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TherVacB (HBsAg ± c-di-AMP)
Description: Administration of the described combinations via the intramuscular route

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TherVacB (HBsAg ± c-di-AMP)
Description: Administration of the described combinations via the intramuscular route

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TherVacB (HBsAg ± c-di-AMP)
Description: Administration of the described combinations via the intramuscular route

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TherVacB (HBsAg ± c-di-AMP)
Description: Administration of the described combinations via the intramuscular route
Study: NCT06430944

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placing a hip spica cast for patients with femur fractures
Description: Placing a hip spica cast for patients with femur fractures. These hip spicas are made for each patient to stabilize the fracture in pediatric patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placing a hip spica cast for patients with femur fractures
Description: Placing a hip spica cast for patients with femur fractures. These hip spicas are made for each patient to stabilize the fracture in pediatric patients
Study: NCT05716009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Escalation -tagraxofusp-erzs
Description: Sequential dose levels of tagraxofusp-erzs dependent on patient response. Fixed doses of gemtuzumab ozogamicin 3mg/m2/day on days 1, 4, and 7 of cycle 1 then on Day 1 or all subsequent cycles for a total of 3 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Expansion at RP2D -tagraxofusp-erzs
Description: Following the dose escalation portion, the expansion dose and schedule (RP2D) will be determined. Patients will continue to receive fixed doses of gemtuzumab ozogamicin 3mg/m2/day on days 1, 4, and 7 of cycle 1 then on Day 1 or all subsequent cycles for a total of 3 cycles.
Study: NCT05807880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The combination treatment of anlotinib, penpulimab and capecitabine.
Description: Patients will receive the combination treatment of anlotinib, penpulimab and capecitabine every three weeks until PD or intolerance to drug toxicity. For each cycle, patients receive anlotinib 10mg, po, qd from day 1 to day 14, penpulimab 200mg, iv in day 1, and capecitabine 650mg/m2, po, bid.
Study: NCT05734183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIME
Description: Multisensorial IMmersive Experiences

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MIME + tDCS
Description: Multisensorial IMmersive Experiences plus transcranial direct current stimulation
Study: NCT04721821

Intervention type: DRUG
Intervention: Tofacitinib
Description: Patients who received Tofacitinib for RA